Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection.
Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection.
复制标题
DOI：
10.1007/s40121-021-00514-7
复制
发表时间：
2022-03
影响因子：
5.4
通讯作者：
Lacza Z
中科院分区：
文献类型：
--
作者：
Fodor E;Müller V;Iványi Z;Berki T;Kuten Pella O;Hornyák I;Ambrus M;Sárkány Á;Skázel Á;Madár Á;Kardos D;Kemenesi G;Földes F;Nagy S;Matusovits A;János N;Tordai A;Jakab F;Lacza Z
从恢复期COVID-19患者（CCP）采集的血浆已通过使用各种方案的临床研究在SARS-CoV 2大流行的早期阶段用作一线治疗。我们提供了来自267名接受CCP治疗的住院重症COVID-19患者的队列数据。未报告输血相关并发症，表明CCP治疗的总体安全性。最终死于COVID-19的患者接受CCP的时间明显较晚（入院后3.95天vs 5.22天），白细胞介素6（IL-6）水平（28.9 pg/ml vs 102.5 pg/ml）高于存活者。此外，无论疾病的严重程度或结果如何，CCP输注均导致患者的总体炎症状态显著降低，如C反应蛋白、IL 6和铁蛋白水平降低所证明的。我们的结论是，对于住院的COVID-19患者，CCP输血是一种安全有效的补充治疗方式，如果尽早应用，其预期结局更好。我们还观察到，IL-6可能是一个合适的实验室参数，患者选择和监测CCP治疗的有效性。
Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the early phase of the SARS-CoV2 pandemic through clinical studies using various protocols. We present data from a cohort of 267 hospitalized severe COVID-19 patients who received CCP. No transfusion-related complications were reported, indicating the overall safety of CCP therapy. Patients who eventually died from COVID-19 received CCP significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels. We conclude that CCP transfusion is a safe and effective supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if applied as early as possible. We also observed that IL-6 may be a suitable laboratory parameter for patient selection and monitoring of CCP therapy effectiveness.
登录
查看更多内容
影响因子：
4.5
作者：
Pappa V;Bouchla A;Terpos E;Thomopoulos TP;Rosati M;Stellas D;Antoniadou A;Mentis A;Papageorgiou SG;Politou M;Kotanidou A;Kalomenidis I;Poulakou G;Jahaj E;Korompoki E;Grigoropoulou S;Hu X;Bear J;Karaliota S;Burns R;Pagoni M;Trontzas I;Grouzi E;Labropoulou S;Stamoulis K;Bamias A;Tsiodras S;Felber BK;Pavlakis GN;Dimopoulos MA
通讯作者：
Dimopoulos MA
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
120.7
作者：
Li, Ling;Zhang, Wei;Liu, Zhong
通讯作者：
Liu, Zhong
影响因子：
4.3
作者：
Neubauer, Markus;Kuten, Olga;Nehrer, Stefan
通讯作者：
Nehrer, Stefan
影响因子：
4.6
作者：
Arican O;Aral M;Sasmaz S;Ciragil P
通讯作者：
Ciragil P